Skip to main content
SpringerLink
Log in

Strahlentherapie und Razoxan beim inoperablen lokalen Rezidiv des Rektumkarzinoms

  • Conference paper
Aktuelle Therapie gastrointestinaler Tumoren

  • 27 Accesses

Zusammenfassung

Das Lokalrezidiv des Rektumkarzinoms ist in der Regel mit einer hohen Morbidität und einer schlechten Prognose verbunden. Die bisher einzige Chance für ein Langzeitüberleben bietet die chirurgische Resektion des Rezidivs, welche aber aus technischen Gründen nur 10–30% der Patienten angeboten werden kann. Eine alleinige Strahlentherapie bewirkt zwar gute palliative Effekte, doch kann eine langfristige lokale Kontrolle nur selten erreicht werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Battermann JJ, Mijnheer BJ (1986) The Amsterdam fast neutron therapy project: a final report. Int J Radiation Oncol Biol Phys 12: 2093–2099

    Article  CAS  Google Scholar 

  2. Bellet RE, Engstrom PF, Catalano RB et al. (1976) Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy. Cancer Treat Rep 60: 1395–97

    PubMed  CAS  Google Scholar 

  3. Bohndorf W, Richter E, Aydin H (1984) CT-Diagnostik and Strahlentherapie lokaler Rezidive nach Operation eines Rektumkarzinoms. Strahlentherapie 160: 318–323

    PubMed  CAS  Google Scholar 

  4. Danjoux CE, Gelber RD, Cotton GE, Klaassen DJ (1985): Combination chemoradiotherapy for residual, recurrent or inoperable carcinoma of the rectum: ECOG Study (EST 3276). Int J Radiation Oncol Biol Phys 11: 765–771

    Article  CAS  Google Scholar 

  5. Dobrowsky W, Wang CS, Cummings BJ (1989) Combined radiation, Mitomycin C and 5-Fluorouracil for recurrent rectal carcinoma. Results of a prospective trial. Poster. EORTC Symposium on Advances in Research and Treatment of Gastrointestinal Tract Cancer. Strasbourg, Sept. 15–17

    Google Scholar 

  6. Duncan W, Arnott SJ, Jack JL, Orr JA, Kerr GR, Williams JR (1987) Results of two randomized clinical trials of neutron therapy in rectal adenocarcinoma. Radiotherapy and Oncology 8: 191–198

    Article  PubMed  CAS  Google Scholar 

  7. Flentje, Frey M, Kuttig H, Kimmig B (1988) Strahlentherapie bei Lokalrezidiven kolorektaler Tumoren. Prognostische Faktoren, Verlaufsdiagnostik and Ergebnisse. Strahlenther Onkol 164: 402–407

    PubMed  CAS  Google Scholar 

  8. Gilbert JM, Hellmann K, Evans M et al. (1982) Adjuvant oral Razoxane (ICRF-159) in resectable colorectal cancer. Cancer Chemother Pharmacol 8: 293–299

    Article  PubMed  CAS  Google Scholar 

  9. Gunderson LL, Kirk Martin J, O’Conell MJ et al. (1985) Residual, recurrent or unresectable gastrointestinal cancer. Role of radiation in single or combined modality treatment. Cancer 55: 2250–58

    Article  PubMed  CAS  Google Scholar 

  10. Hassenstein E, Dannenmaier B (1985) Zur palliativen Schmerzbestrahlung bei lokal rezidivierenden Rektumkarzinomen. Tumor Diagn & Therapie 6: 173–176

    Google Scholar 

  11. Hellmann K, Burrage K (1969) Control of malignant metastases by ICRF-159. Nature 224: 273–275

    Article  PubMed  CAS  Google Scholar 

  12. Hellmann K, Murkin CE (1974) Synergism of ICRF-159 and radiotherapy in experimental tumors. Cancer 34: 1033–1039

    Article  PubMed  CAS  Google Scholar 

  13. Hellmann K, Gilbert J, Evans M et al. (1986) Randomized trial of oral adjuvant razoxane (ICRF 159) in resectable colorectal cancer: five year follow up. Clin Expl Metastasis 4: 326

    Google Scholar 

  14. Le Serve AW, Hellmann K (1972) Metastases and normalization of tumor blood vessels by ICRF-159: A new type of drug action. Br. Med. J.: 1: 597–601

    Article  PubMed  Google Scholar 

  15. Marciniak TA, Moertel CG, Schutt AJ et al. (1975) Phase II study of ICRF-159 in advanced colorectal carcinoma. Cancer Chemother Rep 59: 761–763

    PubMed  CAS  Google Scholar 

  16. Norpoth K, Schaphaus A, Ziegler H et al. (1974) Combined treatment of the Walker tumor with radiotherapy and ICRF-159. Z Krebsf 82: 328

    Google Scholar 

  17. Overgaad M, Bertelsen K, Dalmark M et al. (1989) A randomized trial of radiotherapy alone or combined with 5-FU in the treatment of locally advanced colorectal carcinoma. 5th European Conference on Clinical Oncology, ECCO 5,3.- 5. September, London

    Google Scholar 

  18. Paul AR, Catalano RB, Engstrom PF (1980) Phase III study of ICRF 159 versus 5-FU in the treatment of advanced metastatic colorectal carcinoma. Cancer Treat Rep 64: 1047–1049

    PubMed  CAS  Google Scholar 

  19. Rhomberg WU (1976) Radiotherapy combined with ICRF 159. Int J Radiat Oncol Biol Phys 4: 121–126

    Google Scholar 

  20. Rhomberg W, Eiter H (1989) Studien zur Strahlensensibilität inoperabler und rezidivierender Rektumkarzinome. Strahlenther Onkol 165: 28

    PubMed  CAS  Google Scholar 

  21. Ryall RDH, Hanham IWF, Newton KA et al. (1974) Combined treatment of soft tissue and osteosarcomas by radiation and ICRF-159. Cancer 34: 1040–1045

    Article  PubMed  CAS  Google Scholar 

  22. Salsbury AJ, Burrage K, Hellmann K (1974) Histological analysis of the antimetastatic effect of 1,2-Bis(3,5-dioxopiperazin-l-yl)-propane. Cancer Res 34: 843–849

    PubMed  CAS  Google Scholar 

  23. Schmidt H, Müller RP, Hildebrand D (1984) Ergebnisse der Strahlenbehandlung bei Rezidiven kolorektaler Tumoren. Strahlenther 160: 288

    CAS  Google Scholar 

  24. Vongtama V, Douglas HO, Moore RH et al. (1975) End results of radiation therapy alone and combination with 5-Fluorouracil in colorectal cancers. Cancer 36: 2020–2025

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. W. Rhomberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Eiter
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung Hämatologie und Onkologie, Medizinische Hochschule Hannover, Konstanty-Gutschow-Str. 8, 3000, Hannover 61, Deutschland

    Hans-Joachim Schmoll

  2. Klinik für Abdominal- und Transplantationschirurgie, Zentrum Chirurgie der Medizinischen Hochschule Hannover, Konstanty-Gutschow-Str. 8, 3000, Hannover 61, Deutschland

    Hans-Joachim Meyer  & Rudolf Pichlmayr  & 

  3. Westdeutsches Tumorzentrum Essen, Innere Klinik und Poliklinik, Hufelandstr. 55, 4300, Essen 1, Deutschland

    Hansjochen Wilke

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Rhomberg, W., Eiter, H. (1992). Strahlentherapie und Razoxan beim inoperablen lokalen Rezidiv des Rektumkarzinoms. In: Schmoll, HJ., Meyer, HJ., Wilke, H., Pichlmayr, R. (eds) Aktuelle Therapie gastrointestinaler Tumoren. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76187-4_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76187-4_32

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-76188-1

  • Online ISBN: 978-3-642-76187-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation